A Phase I/II Study of BMS-247550 and Pegylated Liposomal Doxorubicin (Doxila) in Patients with Advanced Epithelial Ovarian Cancer or Primary Peritoneal Cancer Who Have Been Previously Treated with a Taxane
Study Status
Open to Enrollment
Study Description
This clinical trial is studying the side effects and best dose of ixabepilone when given together with liposomal doxorubicin and to see how well they work in treating women with advanced ovarian epithelial or primary peritoneal cavity cancer.
Drugs used in chemotherapy, such as ixabepilone and liposomal doxorubicin, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Giving more than one drug (combination chemotherapy) may kill more tumor cells.
Disease Status and/or Stage
Advanced Epithelial Ovarian Cancer or Peritoneal Cancer
Key Eligibility
- Women age 18 and older
- Confirmed diagnosis of advanced ovarian epithelial cancer or primary peritoneal cavity cancer
- Previously treated with a standard course of taxane-and-platinum-based chemotherapy
- Additional eligibility criteria discussed when you contact the study team
Principal Investigator
Contact
- Yulia Dault, RN
- (212) 746-3145
Healthy Volunteers
As a healthy volunteer in a clinical trial you may make a significant contribution to the discovery of medical knowledge and new treatments that could impact people around the world.
Click here for studies seeking healthy volunteers.
Contact Us
For general inquiries, or if you need assistance finding a study, please contact:
Robert Hagerty
Subject Recruitment Manager
Tel: (646) 962-9340
[email protected]
